Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 29 (2), 248-257

The Nephrologist's Guide to Cannabis and Cannabinoids

Affiliations

The Nephrologist's Guide to Cannabis and Cannabinoids

Joshua L Rein. Curr Opin Nephrol Hypertens.

Abstract

Purpose of review: Cannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients.

Recent findings: Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be closely monitored in those with CKD, the lowest effective dose should be used, and smoking should be avoided. Cannabis use may delay transplant candidate listing or contribute to ineligibility. Cannabidiol (CBD) has recently exploded in popularity. Although generally well tolerated, safe without significant side effects, and effective for a variety of neurological and psychiatric conditions, consumers have easy access to a wide range of unregulated CBD products, some with inaccurate labeling and false health claims. Importantly, CBD may raise tacrolimus levels.

Summary: Patients and healthcare professionals have little guidance or evidence regarding the impact of cannabis use on people with kidney disease. This knowledge gap will remain as long as federal regulations remain prohibitively restrictive towards prospective research.

Figures

FIGURE 1
FIGURE 1
Cannabis sativa W.O.Müll. (A) flowering male and (B) seed-bearing female plant, actual size; (1) male flower, enlarged detail; (2) and (3) pollen sac of same from various angles; (4) pollen grain of same; (5) female flower with cover petal; (6) female flower, cover petal removed; (7) female fruit cluster, longitudinal section; (8) fruit with cover petal; (9) same without cover petal; (10) same; (11) same in cross-section; (12) same in longitudinal section; (13) seed without hull. From Franz Eugen Köhler's Medizinal-Pflantzen. Published and copyrighted by Gera-Untermhaus, FE Köhler in 1887 (1883–1914). Original figure is now in the public domain. https://commons.wikimedia.org/wiki/File:Cannabis_sativa_Koehler_drawing.jpg.
Box 1
Box 1
no caption available

Similar articles

See all similar articles

References

    1. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 2015; 72:1235–1242. - PMC - PubMed
    1. Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States, 2015–2016. Drug Alcohol Depend 2018; 191:374–381. - PMC - PubMed
    2. Prevalence of past-year cannabis use is increasing among middle-aged adults between 50 and 64 years and older adults ≥65 years.

    1. Lloyd SL, Striley CW. Marijuana use among adults 50 years or older in the 21st century. Gerontol Geriatr Med 2018; 4:2333721418781668. - PMC - PubMed
    1. Lum HD, Arora K, Croker JA, et al. Patterns of marijuana use and health impact: a survey among older Coloradans. Gerontol Geriatr Med 2019; 5:2333721419843707. - PMC - PubMed
    2. Descriptive account of legal medical and recreational cannabis use among people at least 60 years. Identified overall positive health impacts.

    1. Reynolds IR, Fixen DR, Parnes BL, et al. Characteristics and patterns of marijuana use in community-dwelling older adults. J Am Geriatr Soc 2018; 66:2167–2171. - PMC - PubMed
    2. Descriptive account of legal medical and recreational cannabis use among patients at a geriatric primary care clinic.

Feedback